opportunities in several disease areas • Assessed the opportunity for biosimilars in key therapeutic areas for a Top-15 pharmaceutical company • Evaluated market and treatment dynamics for a central nervous system asset based on anonymous patient-level data Selected Traditional Consulting Projects • Articulated the competitive strategy for a rare disease product that was encountering competition for the first time since launch • Developed target opportunities for a Top-10 pharmaceutical company in autoimmune diseases including psoriatic arthritis, Crohn’s disease, and ulcerative colitis • Spearheaded project to explore the disruptive innovation taking place in and around the pharmaceutical industry for a Top-5 pharmaceutical company